Most Longevity Experts Don't Tell You This About Aging | 56 - Longevity Science #8

Health Longevity
19 followers
25 Video Views·Aug 10, 2024
I don't know what it's called.
Is it an amino acid?
Interestingly...
Right, many of these things have...
So it was very beneficial for...
My name is Matt Kaberlein, and welcome to the OptiSpan Podcast.
Hey everyone, welcome to the OptiSpan Podcast.
On today's episode, we are going to do a deep dive into the idea of what does it mean to
be an aging gene.
And I want you to stick around to the end, because I'm going to hopefully blow your mind
with an insight that I would say most of the people who work in the field of longevity
haven't made, don't understand.
And so again, this will be one of those opportunities where you can know something that most of
the so-called experts in the field maybe don't know or appreciate.
Okay, so I want to start really by talking about two ways that we can define an aging
gene, and then I'm going to focus in on one of them that I think is more relevant.
So one way that people talk about aging genes would be any gene where the expression of
that gene...
And what I mean by expression is just how high the volume knob is turned up on that
gene.
Is it expressed at a high level, or is it expressed at a low level?
So any gene whose expression level changes in a predictable way with age.
And as I'll get to in a minute, I think this is more properly a biomarker of aging than
what I would think of as an aging gene.
But you'll hear the term used sometimes to describe genes like this.
It's also worth just saying when we talk about a gene, we are also including in there the
protein that is encoded by that gene.
So again, if we think of DNA to RNA to protein, the gene is the DNA.
It gets turned into RNA, that's expression, and then the RNA gets turned into protein,
and the protein is, in most cases, where the action is actually happening.
So when we talk about an aging gene, we also mean an aging protein.
It's just easier and less confusing to call it an aging gene.
Okay, so again, one category would be a gene whose expression, the change in the volume,
changes in a predictable way with age.
The second type of aging gene, which is where we're going to spend most of our time, is
a gene or protein that actually affects the rate or process of biological aging in a causal
manner.
Okay, and I think that causal piece is the key differentiator here.
You can have a biomarker of aging that changes with age, but doesn't actually impact health
span or lifespan or anything about biological aging.
When I talk about an aging gene, what I really mean is a gene or a protein that fundamentally
impacts the biological aging process in a causal way.
Okay, so those are the two types.
We'll just briefly touch on type 1.
Again, type 1 is a biomarker, a gene whose expression level changes in a predictable
way with age.
And I do think it is important to note that these kinds of biomarkers could be biomarkers
of chronological age or of biological age.
And if you're unsure what the difference is, I would encourage you to watch our episode.
It is episode 9, longevity science number 3, biological age and what it really means.
And hopefully somewhere there's a link to that episode if you're interested.
Okay, but really what I mean by that is that the expression of the gene and how it changes
over time could be correlated strongly with chronological age, or it could be more correlated
with biological age.
And you can have biomarkers of either, sometimes of both, but they don't necessarily have to
be of both.
Okay, and it's easy to appreciate what these things might look like.
There are many different patterns of gene expression change that can occur as a function
of age.
So if you think of a graph that's, again, if you think of it as a volume knob that's
showing you how high or low the volume is on the y-axis as a function of age.
And again, we'll just think of chronological age, but in principle, this could be biological
age on the x-axis.
So you could start with genes that aren't expressed very highly, so volumes low early
on.
And then as we get older, it gradually gets turned up.
You could think of genes that stay low until middle age, and then the volume gets turned
up.
They could stay low until very late age, and then the volume gets turned up.
And then there's, of course, the reverse of that.
They could be high and then get turned down in late age, middle age, or early age.
And then, absolutely, there's every possible variation—low, high, low, low, high, low,
high, low, high, right?
So you can imagine all sorts of different patterns where these genes could change in
how highly or lowly they are expressed as a function of age.
And if you take a whole bunch of genes and you look for genes whose patterns are similar
across age or genes whose changes, whose patterns are most strongly associated with age, you
can develop things like this heat map that now start to aggregate genes based on the
way that their expression changes as a function of age.
And if you have enough of those genes, or if they are strongly correlated enough with
age, you can start to create aging clocks.
And that's exactly what all of these aging clocks are.
They aren't all necessarily looking at gene expression, how much RNA or protein is made
as a function of age, but they're all looking at the way different phenotypes or traits
change with age across a large enough number of features.
And so you can find interesting patterns of genes that are co-regulated in the same way
with age.
And in principle, you can start to create predictive signatures, collections of genes
where if we just look at one sample, and if the prediction is strong enough, we can
predict what your chronological age or, in principle, your biological age is just by
looking at the expression level of enough genes at one time point.
So that is the type 1 aging genes.
We're not going to talk about those anymore because I think while they're very powerful,
they are less useful from the perspective of how do we actually modulate biological
aging to improve lifespan and healthspan.
And I do think it's important to recognize these type 1 aging genes almost by definition
are correlative, not causative.
In theory, you could have genes that are both biomarkers of aging and causal aging genes,
but certainly the majority of these type 1 aging genes that we've been talking about
are going to correlate with age, not necessarily causative.
They could also be a response to different aspects of aging, maybe a response to damage
that doesn't really impact the aging process itself.
So correlation, not causation, type 1, type 2 are the causative genes for biological aging.
And we'll talk about how you can recognize those.
So again, the type 2 aging gene, the definition here is going to be a gene that affects the
rate or process of biological aging.
I usually think about it in the context of rate, but in principle, it could be even a
partial reversal of aspects of biological aging.
So the process of biological aging, the key here is in a causal manner.
In other words, turning up or turning down the gene or the protein changes fundamentally
the way we age biologically, faster or slower.
Okay, so these are the super interesting aging genes.
And so you could say, and this is where I think it's important, definitions matter.
You've probably heard me say that before if you have followed this podcast.
So I think it's important to be precise in our language here.
You could actually, even within this type 2 definition of an aging gene, talk about
two fundamentally different types of relationships.
You could say a type 2 aging gene is a gene that actually promotes or accelerates biological
aging.
In other words, when you turn it down, you actually increase lifespan or improve health
span.
So the gene itself is causing biological aging.
You turn it down, things get better.
So you could call that a type 2 aging gene, and you could differentiate that from the
opposite, which you could call a type 2 longevity gene.
That would be a gene whose normal function inhibits or slows biological aging.
So when you turn it up or, as we'll get to, what we call overexpress that gene, you actually
increase lifespan.
So if we were to use those definitions, a type 2 aging gene, its function would be to
accelerate biological aging.
You turn it down, things get better.
A type 2 longevity gene, its function is to actually slow biological aging.
You turn it up, things get better.
Again, you could imagine all sorts of things in between.
And as we'll sort of touch on, there's all sorts of levels of complexity.
It may be the case that an aging gene would function one way in young animals or individuals
and a different way in older animals and individuals.
Let's not get too far down that path.
Okay, the other point I want to make here as we're thinking about definitions and concepts
is we always have to focus on things that improve outcomes.
And what I mean by that is we're interested in finding genes where we can modulate their
expression and increase lifespan or improve healthspan.
Now, why is that?
That's because shortening lifespan or reducing healthspan is nonspecific.
I'm sure if you spend 30 seconds thinking about it, you can come up with all sorts of
ways that you can shorten your lifespan or reduce your healthspan that have nothing to
do with biological aging.
So the sort of example that I often use is if you were to play a game where you wear
a blindfold and you walk back and forth across Interstate 90, that's going to shorten your
lifespan, but it did not accelerate your biological aging.
Okay, so there are many, many ways to break a complex system that have nothing to do with
the normal aging process.
And so we're really interested in finding things that make the system better.
Because almost by definition at the population level, if you can significantly increase lifespan
or significantly improve healthspan, you have to be doing that by targeting biological aging.
So it's just really important, don't get confused by things that shorten lifespan.
They might have something to do with biological aging, but by and large, if you just randomly
selected ways to shorten your lifespan, the vast majority would not be directly impacting
biological aging.
Okay, so if we think now about type 2 aging genes.
So I did differentiate between type 2 aging and type 2 longevity genes.
Now I'm going to put them all back in one bucket just for simplicity.
So I'm going to call them all aging genes, but in principle they could be, the gene itself
could have a positive or a negative effect on the biological aging process.
So perhaps the classic aging gene is DAF2.
So DAF2 is a gene that was identified from C. elegans in a paper from Cynthia Kenyon
that was published in Nature way back in 1993 titled a C. elegans mutant that lives twice
as long as wild type.
So what Cynthia showed was that this single mutation, a single gene, you reduce the function
of that gene, you double the lifespan of C. elegans, which of course is a nematode worm
that we've talked about before on the podcast, one of the common model organisms used in
longevity research.
So that is a perfect example where we have increased lifespan, not by a little bit, but
by a lot, and it was the result of a turning down the expression of a single gene.
Now, it turns out this gene is mechanistically super interesting.
It is the worm version of the insulin and IGF1 receptor.
So in C. elegans, those two receptors have been combined into one gene.
And we now know from a bunch of studies that insulin IGF1 signaling, not just in worms,
but in fruit flies and in mice and in dogs and in people, seems to impact the biological
aging process.
So this is a fundamentally important conserved genetic regulator of longevity.
Another example, now this is the opposite kind.
This is what we would call a type 2 longevity gene is SIR2, which I've talked about before
on the podcast.
This is actually work from my PhD thesis.
When I was a graduate student with Lenny Guarente, Mitch McVeigh and I showed that if you put
in a second copy of SIR2, you can actually increase lifespan, in this case in budding
yeast.
And again, remember, we're interested in increasing lifespan.
So in this case, we turned up the gene and we slowed biological aging and increased lifespan.
SIR2 is, of course, the founding member of the sirtuin family of enzymes that some people
are excited about.
So that's an example of a gene where you turn it up.
So DAF2, you turn it down, slower aging, increased lifespan.
SIR2, you turn it up, slower aging, increased lifespan, at least in yeast.
And there are examples in mammals of both of those types of aging genes as well.
So an example where you turn it up is FGF21, fibroblast growth factor 21.
This is a hormone that gets turned on in response to starvation.
And it's been shown in mice.
If you just overexpress FGF21 at a high enough level, you get a very large increase in lifespan.
And I actually talked with Crystal Hill recently on the podcast about FGF21 in the context of
protein restriction.
So I'd encourage you to check out that interview.
So again, this is a type 2 longevity gene.
You turn it up and you get increased lifespan in mice.
So even in mammals, it's pretty interesting.
There are these strong single gene effects that can have a big impact on biological aging.
Of course, there are many examples also in mice where you do the opposite.
You turn it down and you get increased lifespan.
One example, which again, I've talked about before on the podcast in the episode,
The Surprising Way Body Size Relates to Lifespan, that was longevity science number seven,
are the growth hormone mutants.
So there are a bunch of mutants in the growth hormone pathway
that when you turn down growth hormone signaling, you get dramatic increases in lifespan in mice.
In this case, this is the lit mice.
These are the growth hormone releasing hormone receptor mutants.
I know it's complicated, G-H-R-H-R.
You can just think of them as having lower growth hormone,
where you get this large increase in lifespan.
And again, interestingly, people with these mutations also seem to be protected against
at least a few different age-related diseases.
So they don't tend to get cancer.
They don't tend to get diabetes.
They don't tend to get heart disease, which is suggestive that turning down this pathway,
at least during development, can delay slow biological aging, not just in mice, but also in people.
So again, that's an example of a type two aging gene where we turn down the gene or turn down
the signaling through the pathway and get these large effects on lifespan.
So what about in humans?
So I just mentioned there's some evidence for the growth hormone pathway, again,
at least if you turn it down during development.
There are a couple of other genes that, there are actually several now,
that have been associated with longevity.
There are a couple where I think people are pretty confident of the causal relationship.
So one of those is FOXO3A.
This originally came out of what are called GWAS experiments or genome-wide association studies
where people were looking for genetic variants that were associated with longevity or specific
age-related diseases.
And certain variants in FOXO3A kept coming out as being strongly associated with longevity
or reduced risk of certain age-related diseases.
FOXO3A is super interesting because if you think back to that DAF2 mutant that I talked about,
directly downstream of DAF2 is the worm version of FOXO3A.
It's called DAF16.
And we know that DAF16 is 100% required for and mediates that doubling of lifespan
in the DAF2 mutant.
So again, there seems to be pretty strong evidence that this pathway is conserved and
it regulates longevity in people as well as in worms.
And so FOXO3A variants, for example, have been shown to be overrepresented in centenarians,
people who live to be over 100 years, compared to people who are not centenarians.
Another classic example is the APOE gene where it's pretty clear that if you have two copies
of what's called the E2 variant of APOE, you are protected against several different
age-related diseases.
And if you have two copies of the E4 allele, you are at higher risk of several different
age-related diseases.
And you can see this at the level of survival just by looking at people who have E2, E2
versus E4, E4.
So again, this would be a type 2 aging gene in humans.
So I think it's pretty clear that longevity, biological aging has a strong genetic component
in very, very simple animals, in complex animals, mammals like rodents, mice, and rats, all
the way up to humans.
And at least to some extent, the pathways in genes are also shared across that broad
evolutionary spectrum.
So there are some things to keep in mind now about how we talk about aging genes or how
we think about them.
And I'm not going to get all the way down into the various levels of complexity, but
there are a few that are worth just appreciating.
First of all, when we define an aging gene as a gene that impacts biological aging causally
when we change its expression level or pattern, this is sort of by implication.
We're talking about a change in expression relative to what we consider normal, right?
What's its normal pattern of expression?
But of course, normal depends on a bunch of stuff.
And when you see this in the scientific literature, we'll usually be referring to changing the
expression level relative to what we call wild type, right?
So that's whatever strain background we're working in under the very controlled laboratory
conditions.
But of course, people aren't really wild type.
There's all sorts of genetic backgrounds out there.
And even more important, there's all sorts of environments.
And normal levels of expression of any given gene are going to be strongly influenced by
the other genetics of that individual and probably even more so the environment.
And I say this because it's important to appreciate that the impact of changing expression of an
aging gene is going to be somewhat dependent on the environment, at least in some cases.
So there may be, in fact, I would go so far as to say there absolutely are type 2 aging
genes or longevity genes that act as an aging gene or a longevity gene in one environment,
but not in a different environment.
So for example, there are very likely to be genetic variants that have an impact on biological
aging in people consuming a standard American diet, SAD, standard American diet, versus
those consuming a healthy diet.
And I would suggest we're actually starting to see evidence for that in the context of
the ApoE gene.
It seems pretty clear now that people who have two copies of the E4 allele can do a
lot to mitigate their increased risk of dementia and other age-related diseases by adopting
a healthy diet and a healthy lifestyle overall.
So the impact of that genetic makeup is going to be different in people who are practicing
a healthy lifestyle versus people who are practicing an unhealthy lifestyle.
And that's just a single example.
I'm sure there are many, many others.
So that's one thing to keep in mind.
Another thing to keep in mind is that the aging genes we know about today or aging and
longevity genes we know about today are very biased.
They have almost all, not exclusively, a few have been identified through what we would
call unbiased or through biased approaches where people went looking for a specific pathway.
But the vast majority have come through large-scale unbiased genetic screens.
And unbiased genetic screens have a lot of power, for sure.
But even there, what we know about is biased by the way that those genetic screens were
done.
By and large, the majority of aging genes that are in the literature come from genome-wide
deletion studies in budding yeast or genome-wide RNAi screens in worms.
And RNAi stands for RNA interference.
It's just a way to turn down individual genes one at a time.
So it's a tool that you can use to easily turn down a single gene in principle.
And so people have done large-scale screens of thousands of individual genes in both yeast
and worms and looked for cases where you got big effects on lifespan.
So these are these unbiased genetic screens for longevity.
And a lot of genes have been identified that when you knock them down in yeast, so that's
completely knocking the gene out, taking it out of the genome, or when you turn it
down in worms, leads to increased lifespan.
And this has led to an estimate that about 3% to 5% of genes in the genome may regulate
biological aging.
So in both the worms and in yeast, it was somewhere between 3% and 5% of the genes now
that have been found to have a significant impact on lifespan.
So I think at first glance, that seems like a pretty darn big number.
I think a lot of people were surprised that, you know, maybe as much as 5% of the genes
in the genome can have a significant impact on lifespan.
Okay, so here's where I hope I'm going to blow your mind.
I actually think the percentage of type 2 aging genes is much greater than 5%.
And I have two lines of reasoning to support this.
The first one is that even though people have done these large unbiased genetic screens
in both yeast and worms, we've only explored a tiny, tiny fraction of what I would call
the longevity intervention space, even for genetic longevity interventions, a tiny, tiny
fraction.
So one way to appreciate this is that in both yeast and worms, all of the large-scale unbiased
genetic screens have been what we call loss of function, meaning we're turning the volume
knob down.
In yeast, we're basically turning it off.
We ask, what is the effect for each individual gene if we take it from whatever level the
volume knob's at, let's say 7, and we turn it all the way off?
We do that one by one across the entire genome.
Now, lots of genes, when we do that, result in a dead yeast cell.
Those are called essential genes.
Same thing's true in worms, mice, people.
There are lots and lots of essential genes that if you take it to zero, you get a dead
organism.
Okay.
So we can't even look at those.
But for all the others, we're basically looking at one level of expression.
And the same thing's true in worms with these RNAi tools, except the level of expression
in most cases isn't zero.
It's something less than what it started at.
And we don't even really know, in most cases, how much less.
So basically, it's like, you know, you just turn the volume knob, but you don't really
know how far you turned it.
And again, we're only looking at one different level of expression.
So we're stuck looking at loss of function, turning the knob down to some level, and we're
only looking at one level down from whatever the normal expression level is.
So that's a tiny fraction of the possible volume levels.
And you could certainly imagine all sorts of variations on top of that, where maybe
you turn it down for a little bit, and then you turn it up for a little bit, then you
turn it back down, right?
So we're really not exploring all the possible intervention space in any meaningful way.
And we're not exploring turning the knob up at all.
We have essentially zero large-scale genetic screens looking at the effect of turning up
genes on lifespan.
So tiny, tiny fraction.
And there's pretty good evidence that turning up genes can lead to lifespan extension quite
a bit of the time.
So especially if you combine the essential part, the essential genes, with turning them
up.
So we have one study from my good friend Alateen Kaya, who I've collaborated with, and I was
a collaborator on this study.
By the way, Alateen is one of the most innovative people in the field.
He keeps coming up with very, very cool ideas that I think are high impact.
So this is an example of that, where Alateen had the idea, what if we, one by one,
overexpress essential genes?
And there's good biological rationale for why that might be important and effective.
And so we did a pilot study.
We were fortunate enough to get a grant from the Impetus Grants program to do a pilot study
where we looked at a couple dozen of these essential genes in yeast, and we just overexpressed
them one by one.
And we found that half of them extended lifespan when we did that.
So that's the only study, and it's very small scale, that has even started to look at
turning up genes, or specifically turning up genes and looking at essential genes, but
suggestive that there are probably a lot more aging genes out there than we know about,
and we don't know about them because nobody's really looked.
The other sort of line of reasoning for why I would suggest that there's way more than
5% of the genes in the genomes that are type 2 aging genes is more of an evolutionary argument.
So if you think about how evolution works, right?
We're talking about evolution by natural selection.
I want you to just think for a moment about what is natural selection acting on?
What is the primary driving force of natural selection?
That force is to successfully pass the genetic information on to the next generation.
That's basically what we're all about.
Our goal, from an evolutionary perspective, is to pass our genes on to the next generation.
All of the genes in our genome, in principle, have been optimized through natural selection
to do that, okay?
So if you think about this at the individual gene level, a volume knob, right?
Again, very simple analogy.
Natural selection is going to ensure that—you can imagine a few rare cases where this might
not happen, but in general, natural selection is going to ensure that that volume knob is set
as close as it possibly can be to optimizing your chance of reproducing and passing your
genes on successfully to the next generation, which means not just reproducing, but reproducing
at the optimal level and at the optimal time, okay?
So now if we think about the volume knob in the context of biological aging, what is the
force of natural selection to optimize that volume knob for optimal biological aging,
optimal healthspan and lifespan?
And I think most people would agree it's almost zero.
Like, there's very little reason for evolution to care whether or not we're going to live
to 105, 110, 120 in good health.
And in fact, we can reasonably speculate that essentially none of our genes are going to
be regulated—the volume knob is going to be regulated to be expressed in a way that
optimizes for longevity and healthspan.
So if an individual gene is in fact optimized for longevity and healthspan or for biological
aging, it's pretty much by accident, meaning that optimal biological aging just happens
to be similar to optimal reproductive fitness.
And it follows from that that very, very few, if any, of our genes are going to therefore
be optimized for longevity, because it's very unlikely that that's going to just by
chance line up with optimal reproductive fitness.
And in fact, if anything, I think we've learned that those things tend to be counter-opposed
to each other, that in fact, optimizing for reproductive fitness often is suboptimal for
biological aging.
So given that, it must be the case that for the majority of genes, there is some other
expression level or pattern, other than what these things have been optimized for, that
would be optimal for longevity.
And given that, it's very, very likely that the number of type 2 aging genes is much larger
than the 3 to 5 percent that has been estimated from these very low coverage genetic studies
that have been done in simple model organisms.
So I don't know what that number is, but personally, I'd guess it's over 50 percent
of the genes in our genome that if we could optimize those for biological aging, would
have a positive impact on healthspan and or lifespan.
I don't know how big the impact would be, probably pretty small in most cases, but where
you could actually make things better.
And of course, in some cases, that optimization for biological aging may have side effects
that offset the benefits or make it impractical or undesirable for some reason to optimize
for biological aging.
But in principle, still, if we knew enough about the system, we could figure out what
pattern of optimization gives us the best bang for the buck in terms of risk-reward
or side effects to benefits.
But I think the take-home here is that evolutionary principles essentially guarantee that there
are many, many, many more opportunities to optimize longevity than we are currently,
as a field, exploring.
And so I've said this before, I really think that there's a need in this field to look
outside of the lamppost and explore more of these opportunities to optimize healthspan,
lifespan, and biological aging.
And I think, again, evolution pretty much guarantees that those opportunities are out
there.
We just need people to go out and find them.
OK, so with that, I hope this gives you a new perspective on what we mean by an aging
gene and hopefully a new appreciation really for what the opportunities are to impact biological
aging by modulating the genetics of aging and understanding how these genes interact
to impact the aging process.
So thank you for watching this episode of the OptiSpan podcast.
As always, if you have any questions or comments, please leave them below.
If you're not yet a subscriber, why not hit that subscribe button?
And I hope to see you next time on the OptiSpan podcast.
